Indications › Heart failure
GLP‑1 drugs in heart failure
Which incretin agents are being studied in heart failure, by whom, and when each trial is due to report. Conditions are grouped from the registry’s own wording, which records the same disease several ways.
- Trials on file
- 18
- Active
- 10
- Results scheduled
- 4
- Molecules studied
- 6
- Sponsors
- 18
No GLP‑1 or incretin drug is FDA-approved for heart failure. The trials below are studies, not approvals, and most drugs tested in a new condition never get approved for it.
No GLP-1 or incretin drug is approved for heart failure, so everything below is investigational. Most drugs tested in a new condition never reach approval for it, and a registration is not evidence of benefit. 14 of the 18 trials on file are phase 3 or later — the stage sized for a regulator to act on, against 4 still in early phases. 18 distinct sponsors are involved, 4 of the trials run commercially and the rest by universities and hospitals.
Molecules studied in this indication
exenatide · liraglutide · maridebart cafraglutide · mazdutide · semaglutide · tirzepatide
Results due in this indication
| Est. completion | Drug | Trial | Phase | Participants |
|---|---|---|---|---|
| 2026-09-24 | mazdutide | A Study of IBI362 in Subjects With HFpEF or HFmrEF Combined With Obesity NCT06862908 · Innovent Biologics (Suzhou) Co. Ltd. | P2 | 141 |
| 2026-12-30 | semaglutide | Tailored Exercise Training Study Among Adults With HFpEF NCT07223242 · University of Texas Southwestern Medical Center | P2/P3 | 120 |
| 2027-12-30 | semaglutide | Effect of Weight Loss on Physical and Cardiac Performance in People With Obesity and Heart Failure NCT06423599 · Jens D Hove, MD,PHD | P2/P3 | 100 |
| 2028-06-30 | maridebart cafraglutide | Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity NCT07037459 · Amgen | P3 | 5,056 |
Trials on file
All 18 incretin trials recorded in this indication, active first.